Vitrolife AB: Interim report January-March 2021: Recovery and good profitability

Rhea-AI Summary

In its first quarter report for 2021, Vitrolife AB announced sales of SEK 379 million, a 14% increase compared to the previous year. In local currency, sales rose by 20%. The company's EBITDA reached SEK 163 million with a margin of 43%, impacted negatively by SEK 10 million due to exchange rate fluctuations. Net income increased to SEK 119 million, generating earnings per share of SEK 1.09.

Positive

• Sales increased by 14% to SEK 379 million.
• Local currency sales rose by 20%.
• EBITDA grew to SEK 163 million, with a margin of 43%.
• Net income increased to SEK 119 million, with earnings per share of SEK 1.09.

Negative

• EBITDA was negatively impacted by SEK 10 million from exchange rate fluctuations.

GÖTEBORG, Sweden, April 22, 2021 /PRNewswire/ --

First quarter:

• Sales amounted to SEK 379 (334) million, corresponding to an increase of 14 percent in SEK. Sales increased by 20 percent in local currency.
• Operating income before depreciation and amortisation (EBITDA) amounted to SEK 163 (116) million, corresponding to a margin of 43 (35) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 10 million.
• Net income amounted to SEK 119 (80) million, which gave earnings per share of SEK 1.09 (0.74).

Gothenburg, April 22, 2021

VITROLIFE AB (publ)

Thomas Axelsson, CEO

CONTACT:

Queries should be addressed to:

Thomas Axelsson, CEO, tel 46 31 721 80 01

Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.00 am CET on April 22, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/vitrolife-ab--publ-/r/interim-report-january-march-2021--recovery-and-good-profitability,c3330565

The following files are available for download:

https://mb.cision.com/Main/1031/3330565/1405205.pdf

Interim report January - March 2021

View original content:http://www.prnewswire.com/news-releases/vitrolife-ab--interim-report-januarymarch-2021-recovery-and-good-profitability-301274528.html

SOURCE Vitrolife AB (publ)

FAQ

What were Vitrolife's sales figures for Q1 2021?

Vitrolife reported sales of SEK 379 million in the first quarter of 2021.

How much did Vitrolife's EBITDA increase in Q1 2021?

Vitrolife's EBITDA increased to SEK 163 million, a rise from SEK 116 million the previous year.

What is the earnings per share for Vitrolife in Q1 2021?

Earnings per share for Vitrolife in Q1 2021 were SEK 1.09.

How did exchange rates affect Vitrolife's Q1 2021 results?

Exchange rate fluctuations negatively impacted Vitrolife's EBITDA by SEK 10 million.

What percentage increase did Vitrolife see in local currency sales?

Vitrolife experienced a 20% increase in sales when measured in local currency.